AI Article Synopsis
- The study aimed to assess the effectiveness of (18)F-FDG PET scans in evaluating head and neck squamous cell carcinoma (SCCHN) one month after completing radiotherapy.
- Ninety-seven patients underwent PET scans before and after radiotherapy, with results showing a significant reduction in SUV values, indicating a response to treatment.
- The sensitivity, specificity, and overall accuracy of the PET scans for post-radiotherapy evaluation were found to be high, suggesting that (18)F-FDG PET is a helpful tool for monitoring cancer treatment effectiveness.
Article Abstract
Unlabelled: Our purpose was to prospectively evaluate the efficacy of PET with (18)F-FDG 1 mo after the completion of radiotherapy in patients with squamous cell carcinoma of the head and neck (SCCHN).
Methods: Ninety-seven patients underwent (18)F-FDG PET scans before and after radiotherapy for nondisseminated SCCHN. The first scans were obtained no more than 4 wk before the start of radiotherapy, and follow-up scans were obtained 1 mo after the completion of radiotherapy. (18)F-FDG PET images were analyzed using standardized uptake values (SUVs). All patients were followed for at least 6 mo or until death.
Results: The median SUVs of preradiotherapy primary sites and nodes were 6.5 (range, 2.3-23.0) and 5.6 (range, 1.2-16.8), respectively. The median SUVs of postradiotherapy primary sites and nodes were 1.8 (range, basal status value to 9.7) and 1.8 (range, basal status value to 8.6), respectively. Evaluation of the postradiotherapy status of tumors in these SCCHN patients showed the sensitivity of (18)F-FDG PET to be 88%, the specificity to be 95%, and the overall diagnostic accuracy to be 94.9%.
Conclusion: Our results indicate that (18)F-FDG PET might be a valuable imaging method for evaluating the response to radiotherapy in patients with SCCHN. One month after the completion of radiotherapy is not too early for follow-up (18)F-FDG PET to be performed to evaluate the response to radiotherapy.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Case report: Bone marrow metastasis and bone marrow necrosis occurring 11 years after ductal carcinoma of the breast.
Front Oncol
December 2024
Department of Pathology, Weifang Hospital of Traditional Chinese Medicine, Weifang, Shandong, China.
Ductal carcinoma (DCIS), a noninvasive breast cancer, rarely metastasises to distant locations. When the initial lesion is stable, bone marrow metastasis (BMM) and bone marrow necrosis (BMN) are even less common. Here, we report the case of a 47-year-old female patient who underwent localized surgery and radiotherapy for right-sided DCIS.
View Article and Find Full Text PDFJoint EANM/EANO/RANO/SNMMI practice guideline/procedure standard for PET imaging of brain metastases: version 1.0.
Eur J Nucl Med Mol Imaging
January 2025
Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
This joint practice guideline/procedure standard was collaboratively developed by the European Association of Nuclear Medicine (EANM), the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the European Association of Neuro-Oncology (EANO), and the PET task force of the Response Assessment in Neurooncology Working Group (PET/RANO). Brain metastases are the most common malignant central nervous system (CNS) tumors. PET imaging with radiolabeled amino acids and to lesser extent [F]FDG has gained considerable importance in the assessment of brain metastases, especially for the differential diagnosis between recurrent metastases and treatment-related changes which remains a limitation using conventional MRI.
View Article and Find Full Text PDFUncommon Breast Metastasis From Rectal Carcinoma Clearly Revealed on 68Ga-FAPI-04 PET/CT.
Clin Nucl Med
January 2025
From the Department of Nuclear Medicine, West China Hospital of Sichuan University, Chengdu, Sichuan Province, People's Republic of China.
Breast metastasis from rectal carcinoma is very rare. We report a case of imaging findings of breast metastasis in a 31-year-old woman who underwent laparoscopic radical tumor resection 8 months ago. 68Ga-FAPI-04 PET/CT and 18F-FDG PET/CT showed 4 small breast nodules with intense 68Ga-FAPI uptake (SUVmax, 9.
View Article and Find Full Text PDFContrasting Molecular Imaging Findings in Hepatocellular Carcinoma Using Dual Positron Emission Tomography Modalities.
Cureus
December 2024
Nuclear Medicine and PET/CT, King Hussein Cancer Center (KHCC), Amman, JOR.
Fibroblast activation protein (FAPI) has been recently incorporated as a molecular imaging radiotracer for the evaluation of epithelial neoplasms that support or complement the role of [F]Fluorodeoxyglucose ([F]FDG) in many cancer subtypes since its development. Both radiotracers have been shown to have diagnostic, prognostic, and predictive value for several neoplasms. Herein, we present a 73-year-old male patient with a complex medical and oncological history who was recently diagnosed with hepatocellular carcinoma (HCC).
View Article and Find Full Text PDFTracing prostate cancer - the evolution of PET-CT applications.
Rep Pract Oncol Radiother
December 2024
Nuclear Medicine Department, Greater Poland Cancer Centre, Poznan, Poland.
Background: The study aimed to overview radiopharmaceuticals used for the nuclear medicine (NM) imaging of prostate cancer (Pca) since the first mentions in the literature up to recent reports, with the special focus on positron emission tomography-computed tomography (PET-CT) radiotracers.
Materials And Methods: We found over 3500 articles discussing the role of PET-CT in Pca patients' management published within 1990-2023. We summarized the past and present interests of the Authors when the Pca diagnostic imaging and the use of radiotracers in Pca diagnosis are considered.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!